Children with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome are individually dosed and treated for 12 weeks
Ferring Pharmaceuticals A/S has developed a new ZOMACTON 10 mg formulation. The formulation provides a higher concentration and thereby a smaller volume to be administered. ZomaJet Vision X is a needle-free injection system. It sends a thin jet of ZOMACTON through the skin and into the subcutaneous tissue without the use of a needle. The mode of administration is referred to as "transjection". By use of ZomaJet Vision X, both transjection and reconstitution of ZOMACTON 10 mg can be done without using a needle. The rationale of the study is to describe the local tolerability of the new ZOMACTON 10 mg administered by ZomaJet Vision X.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
27
Faculty Hospital Olomouc, Children's Clinic, Endocrinology Outpatient Department, I.P.Pavlova str. 6,
Olomouc, Czechia
Faculty Hospital Kralovske Vinohrady, Children's Clinic, Vinohradska str. 159
Prague, Czechia
Masaryk Hospital Usti nad Labem, Children's Clinic, Building D2, Endocrinology Outpatient Department, Socialni pece 12a
Ústí nad Labem, Czechia
To assess the local tolerability of an individualised dose of ZOMACTON 10 mg administered by ZomaJet Vision X
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Centre d'Endocrinologie Pediatrique, 25 rue Boudet
Bordeaux, France
Service de Pédiatrie, Groupe Hospitalier du Havre, 55 bis, rue Gustave Flaubert
Le Havre, France
Vu medisch centrum, Paediatrics, De Boelelaan 1117, PO Box 7057
Amsterdam, Netherlands